EP1351670A4 - Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda - Google Patents
Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmdaInfo
- Publication number
- EP1351670A4 EP1351670A4 EP01990191A EP01990191A EP1351670A4 EP 1351670 A4 EP1351670 A4 EP 1351670A4 EP 01990191 A EP01990191 A EP 01990191A EP 01990191 A EP01990191 A EP 01990191A EP 1351670 A4 EP1351670 A4 EP 1351670A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- methods
- receptor antagonists
- nmda receptor
- neuropsychiatric disorders
- treating neuropsychiatric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07000173A EP1852113A3 (fr) | 2000-12-07 | 2001-12-07 | Interface d'utilisateur pour contrôler de nombreux paramètres et procédé de contrôle de nombreux paramètres |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25400700P | 2000-12-07 | 2000-12-07 | |
US254007P | 2000-12-07 | ||
PCT/US2001/048516 WO2002045710A1 (fr) | 2000-12-07 | 2001-12-07 | Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07000173A Division EP1852113A3 (fr) | 2000-12-07 | 2001-12-07 | Interface d'utilisateur pour contrôler de nombreux paramètres et procédé de contrôle de nombreux paramètres |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1351670A1 EP1351670A1 (fr) | 2003-10-15 |
EP1351670A4 true EP1351670A4 (fr) | 2004-07-07 |
Family
ID=22962564
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01990191A Ceased EP1351670A4 (fr) | 2000-12-07 | 2001-12-07 | Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1351670A4 (fr) |
JP (1) | JP2004515477A (fr) |
CN (1) | CN1486180A (fr) |
AU (1) | AU2002229056A1 (fr) |
BR (1) | BR0116001A (fr) |
CA (1) | CA2436311A1 (fr) |
MX (1) | MXPA03005130A (fr) |
WO (1) | WO2002045710A1 (fr) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8257428B2 (en) | 1999-08-09 | 2012-09-04 | Cardiokinetix, Inc. | System for improving cardiac function |
US8500795B2 (en) | 1999-08-09 | 2013-08-06 | Cardiokinetix, Inc. | Retrievable devices for improving cardiac function |
US10307147B2 (en) | 1999-08-09 | 2019-06-04 | Edwards Lifesciences Corporation | System for improving cardiac function by sealing a partitioning membrane within a ventricle |
US7674222B2 (en) | 1999-08-09 | 2010-03-09 | Cardiokinetix, Inc. | Cardiac device and methods of use thereof |
US9694121B2 (en) | 1999-08-09 | 2017-07-04 | Cardiokinetix, Inc. | Systems and methods for improving cardiac function |
US8377114B2 (en) | 1999-08-09 | 2013-02-19 | Cardiokinetix, Inc. | Sealing and filling ventricular partitioning devices to improve cardiac function |
US8529430B2 (en) | 2002-08-01 | 2013-09-10 | Cardiokinetix, Inc. | Therapeutic methods and devices following myocardial infarction |
US6444702B1 (en) | 2000-02-22 | 2002-09-03 | Neuromolecular, Inc. | Aminoadamantane derivatives as therapeutic agents |
US9332992B2 (en) | 2004-08-05 | 2016-05-10 | Cardiokinetix, Inc. | Method for making a laminar ventricular partitioning device |
US10064696B2 (en) | 2000-08-09 | 2018-09-04 | Edwards Lifesciences Corporation | Devices and methods for delivering an endocardial device |
US9078660B2 (en) | 2000-08-09 | 2015-07-14 | Cardiokinetix, Inc. | Devices and methods for delivering an endocardial device |
US9332993B2 (en) | 2004-08-05 | 2016-05-10 | Cardiokinetix, Inc. | Devices and methods for delivering an endocardial device |
TW200403066A (en) * | 2002-04-30 | 2004-03-01 | Novartis Ag | New uses of substituted aminoalkanephosphonic acids |
AR046314A1 (es) * | 2003-11-05 | 2005-11-30 | Merz Pharma Gmbh & Co Kgaa | Composiciones que comprenden ciclohexilaminas y aminoadamantanos |
UY28650A1 (es) * | 2003-12-05 | 2005-02-28 | Forest Laboratories | Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta |
TW200531680A (en) * | 2004-03-03 | 2005-10-01 | Merz Pharma Gmbh & Co Kgaa | Therapy using 1-aminocyclohexane derivatives for the treatment of behavioral disorders associated with alzheimer's disease |
CA2569015A1 (fr) * | 2004-06-17 | 2006-01-26 | Forest Laboratories, Inc. | Formulation de liberation modifiee de memantine |
CA2607600A1 (fr) * | 2005-06-16 | 2006-12-28 | Forest Laboratories, Inc. | Formulation de gouttes de memantine a liberation modifiee et immediate |
EP1986735A4 (fr) | 2006-02-06 | 2011-06-29 | Northwind Ventures | Systèmes et procédés de réduction de volume |
ES2690205T3 (es) * | 2006-04-13 | 2018-11-19 | Neurotech Pharmaceuticals Co., Ltd. | Composición farmacéutica para tratar o prevenir enfermedades inflamatorias |
IT1396556B1 (it) | 2009-02-11 | 2012-12-14 | Serra | Uso di memantina per il trattamento di disturbi dell umore |
CN102070463A (zh) * | 2009-06-11 | 2011-05-25 | 辽宁利锋科技开发有限公司 | 具有金刚烷结构药物美金刚胺及其衍生物和类似物抗肿瘤新适应症的应用 |
US8790242B2 (en) | 2009-10-26 | 2014-07-29 | Cardiokinetix, Inc. | Ventricular volume reduction |
EP3132793A1 (fr) | 2009-12-02 | 2017-02-22 | Adamas Pharmaceuticals, Inc. | Compositions d'amantadine et procédés d'utilisation |
JP5562716B2 (ja) * | 2010-05-12 | 2014-07-30 | 花王株式会社 | 電位依存性カチオンチャネル抑制剤 |
WO2014204933A1 (fr) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Compositions d'amantadine et procédés d'utilisation |
CN112773798B (zh) * | 2014-04-30 | 2024-03-29 | 宇凤·简·曾 | 作为d-氨基酸氧化酶抑制剂的已知化合物的用途 |
CN105294450B (zh) * | 2014-05-29 | 2024-05-17 | 广州喜鹊医药有限公司 | 具有神经保护作用的金刚烷胺硝酸酯化合物及其制备和医药应用 |
WO2016048802A1 (fr) | 2014-09-28 | 2016-03-31 | Cardiokinetix, Inc. | Appareils permettant de traiter un dysfonctionnement cardiaque |
CA3024783A1 (fr) * | 2015-05-22 | 2016-12-01 | Vistagen Therapeutics, Inc. | Utilisations therapeutiques de la l-4-chlorocynurenine |
DE102018107407A1 (de) | 2017-03-28 | 2018-10-04 | Edwards Lifesciences Corporation | Positionieren, einsetzen und zurückholen von implantierbaren vorrichtungen |
CN111356452A (zh) * | 2017-08-01 | 2020-06-30 | 斯图尔特·A·利普顿 | 用于治疗神经病况的方法和组合物 |
EP3713558A4 (fr) * | 2017-11-22 | 2021-10-13 | Panorama Research Inc. | Composés de nitrate d'aminoadamantyle et leur utilisation pour traiter des troubles du système nerveux central |
CN109206317B (zh) * | 2018-09-12 | 2021-07-09 | 青岛海蓝医药有限公司 | 一种金刚烷胺类硝酸酯衍生物的制备工艺 |
CN110938006A (zh) * | 2019-12-04 | 2020-03-31 | 重庆植恩药业有限公司 | 盐酸美金刚杂质c的制备方法 |
CN114544826B (zh) * | 2020-11-24 | 2023-12-08 | 重庆医科大学 | 检测血浆中组氨酸的试剂在制备抑郁症检测试剂盒中的用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994005275A1 (fr) * | 1992-09-03 | 1994-03-17 | The Children's Medical Center Corporation | Procede de prevention contre les lesions neuronales dues au recepteur nmda |
WO1994006428A1 (fr) * | 1992-09-22 | 1994-03-31 | The Children's Medical Center Corporation | Procede de prevention de deteriorations neuronales induites par le complexe recepteur nmda |
WO2001062706A1 (fr) * | 2000-02-22 | 2001-08-30 | Panorama Research, Inc. | Derives d'aminoadamantane convenant comme agents therapeutiques |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS584718A (ja) * | 1981-06-30 | 1983-01-11 | Nippon Chibagaigii Kk | 新規適応症に用うる医薬製剤 |
-
2001
- 2001-12-07 MX MXPA03005130A patent/MXPA03005130A/es unknown
- 2001-12-07 CA CA002436311A patent/CA2436311A1/fr not_active Abandoned
- 2001-12-07 EP EP01990191A patent/EP1351670A4/fr not_active Ceased
- 2001-12-07 WO PCT/US2001/048516 patent/WO2002045710A1/fr active Application Filing
- 2001-12-07 CN CNA018217958A patent/CN1486180A/zh active Pending
- 2001-12-07 AU AU2002229056A patent/AU2002229056A1/en not_active Abandoned
- 2001-12-07 BR BR0116001-0A patent/BR0116001A/pt not_active Application Discontinuation
- 2001-12-07 JP JP2002547494A patent/JP2004515477A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994005275A1 (fr) * | 1992-09-03 | 1994-03-17 | The Children's Medical Center Corporation | Procede de prevention contre les lesions neuronales dues au recepteur nmda |
WO1994006428A1 (fr) * | 1992-09-22 | 1994-03-31 | The Children's Medical Center Corporation | Procede de prevention de deteriorations neuronales induites par le complexe recepteur nmda |
WO2001062706A1 (fr) * | 2000-02-22 | 2001-08-30 | Panorama Research, Inc. | Derives d'aminoadamantane convenant comme agents therapeutiques |
Non-Patent Citations (3)
Title |
---|
PARSONS C G ET AL: "Memantine is a clinically well tolerated N-methyl-D-aspartate (NMDA) receptor antagonist - A review of preclinical data", NEUROPHARMACOLOGY, vol. 38, no. 6, June 1999 (1999-06-01), pages 735 - 767, XP002279262, ISSN: 0028-3908 * |
See also references of WO0245710A1 * |
YAMADA KAZUO ET AL: "Changes in symptoms and plasma homovanillic acid with amantadine hydrochloride in chronic schizophrenia", BIOLOGICAL PSYCHIATRY, vol. 41, no. 10, 1997, pages 1062 - 1064, XP002279263, ISSN: 0006-3223 * |
Also Published As
Publication number | Publication date |
---|---|
EP1351670A1 (fr) | 2003-10-15 |
WO2002045710A9 (fr) | 2003-04-24 |
MXPA03005130A (es) | 2004-12-06 |
CA2436311A1 (fr) | 2002-06-13 |
CN1486180A (zh) | 2004-03-31 |
JP2004515477A (ja) | 2004-05-27 |
AU2002229056A1 (en) | 2002-06-18 |
WO2002045710A1 (fr) | 2002-06-13 |
BR0116001A (pt) | 2004-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1351670A4 (fr) | Methodes de traitement de troubles neuropsychiatriques avec des antagonistes des recepteurs de nmda | |
PL365377A1 (en) | Amide derivatives as nmda receptor antagonists | |
HK1029574A1 (en) | 1-amino-alkylcyclohexane nmda receptor antagonists | |
HK1075037A1 (en) | Unsaturated 1-amino-alkylcyclohexane nmda, 5ht3 and neuronal nicotinic receptor antagonists | |
IL152775A0 (en) | Il-8 receptor antagonists | |
EP1436258A4 (fr) | Antagonistes du recepteur nmda dependant du ph | |
IL147977A0 (en) | Substituted 1,5-dihydropyrrol-2-on derivatives as nmda receptor antagonists for the treatment of pain | |
PT1370268E (pt) | Métodos de tratamento de perturbações de stress usando antagonistas específicos dos receptores de glucocorticóides | |
DZ3309A1 (en) | Il-8 receptor antagonists | |
ZA200104187B (en) | 1-Amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists. | |
IL151431A0 (en) | Il-8 receptor antagonists | |
IL144299A0 (en) | N-triazolymethyl-piperazine derivatives as neurokinin receptor antagonists | |
AU2002360819A8 (en) | Cyclohexano- and cycloheptapyrazole derivative compounds, for use in diseases associated with the 5-ht2c receptor | |
EP1274415A4 (fr) | Antagonistes du recepteur de il-8 | |
AP2002002599A0 (en) | Il-8 receptor antagonists | |
EP1265905A4 (fr) | Antagonistes du recepteur de l'interleukine 8 (il-8) | |
EP1351687A4 (fr) | Antagonistes des recepteurs de l'urotensine ii | |
GB0028146D0 (en) | Bombesin receptor antagonists | |
PL366034A1 (en) | Il-8 receptor antagonists | |
EP1274428A4 (fr) | Antagonistes vis-a-vis du recepteur de l'interleukine-8 (il-8) | |
EP1274413A4 (fr) | Antagonistes du recepteur il-8 | |
PL370367A1 (en) | Ccr-3 receptor antagonists v | |
EP1261329A4 (fr) | Antagonistes du recepteur de il-8 | |
AU8778498A (en) | Nicotine antagonists for nicotine-responsive neuropsychiatric disorders | |
EP1278538A4 (fr) | Anticorps se liant a cd18 et inhibant des troubles apparentes a la stenose |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20030707 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040526 |
|
17Q | First examination report despatched |
Effective date: 20050415 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: WENT, GREGORY T. Inventor name: LIPTON, STUART, M.D. |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: WENT, GREGORY T. Inventor name: LIPTON, STUART, M.D. |
|
APBN | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2E |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NEUROMOLECULAR INC. |
|
APBR | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3E |
|
APAZ | Date of receipt of statement of grounds of appeal deleted |
Free format text: ORIGINAL CODE: EPIDOSDNOA3E |
|
APBR | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3E |
|
APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
APBT | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9E |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20100806 |